8-K
filed May 21, 2026, 8:00 AM ET
ticker OFIX
CIK 0000884624
regulatory
confidence high
sentiment negative
materiality 0.80
Orthofix cuts FY2026 guidance as CMS cuts bone stimulator reimbursement ~10%
Orthofix Medical Inc.
- CMS reduced Medicare reimbursement for HCPCS codes E0747, E0748, E0760 by ~10% effective May 18, 2026.
- FY2026 net sales guidance lowered to $838M-$848M; non-GAAP adjusted EBITDA to $90M-$93M.
- Company no longer expects positive free cash flow in FY2026; three-year financial targets abandoned.
- Further CMS changes could require additional outlook revisions; long-term impact still being evaluated.
Machine-readable event card
- schema_version
- secwatch.filing_event.v1
- accession
- 0001193125-26-233429
- form_type
- 8-K
- ticker
- OFIX
- cik
- 0000884624
- company_name
- Orthofix Medical Inc.
- filed_at
- 2026-05-21T12:00:44+00:00
- discovered_at
- 2026-05-21T12:05:00.297539+00:00
- generated_at
- 2026-05-21T12:07:07.888164+00:00
- sec_items
- ["7.01"]
- event_type
- regulatory
- sentiment
- negative
- materiality_score
- 0.8
- calibrated_materiality_score
- 0.8
- confidence
- high
- secwatch_canonical_url
- https://secwatch.observer/filing/0001193125-26-233429
- json_url
- https://secwatch.observer/filing/0001193125-26-233429.json
- markdown_url
- https://secwatch.observer/filing/0001193125-26-233429.md
- text_url
- https://secwatch.observer/filing/0001193125-26-233429.txt
- edgar_index_url
- https://www.sec.gov/Archives/edgar/data/884624/000119312526233429/0001193125-26-233429-index.htm
- edgar_primary_document_url
- https://www.sec.gov/Archives/edgar/data/884624/000119312526233429/ofix-20260521.htm
- generated_by_model
- deepseek-v4-flash:cloud@v2
- review_status
- machine_generated
- human_reviewed
- false
- corrected
- false
- correction_note
- null
- correction_timestamp
- null
- superseded_by
- null
Comparable filings
NJR
NJNG files base rate case seeking $157.6M increase; offers 8.9% winter bill cut
NEW JERSEY RESOURCES CORP
June 1, 2026, 4:03 PM ET
regulatory
Items 7.01, 9.01
same SEC item: 7.01
same event type: regulatory
similar materiality
Filing page
SEC filing
ATNM
Actinium receives NYSE American non-compliance notice for low stockholders' equity; must submit plan by June 26
Actinium Pharmaceuticals, Inc.
May 29, 2026, 5:10 PM ET
regulatory
Items 3.01, 7.01, 9.01
same SEC item: 7.01
same event type: regulatory
similar materiality
Filing page
SEC filing
REPL
Replimune to resubmit RP1 BLA for advanced melanoma; FDA agrees to prioritize review
Replimune Group, Inc.
May 29, 2026, 9:56 AM ET
regulatory
Items 7.01, 9.01
same SEC item: 7.01
same event type: regulatory
similar materiality
Filing page
SEC filing
CDT
CDT Equity receives Nasdaq deficiency letter for late Q1 10-Q filing; has until July 20 to submit plan
CDT Equity Inc.
May 28, 2026, 4:30 PM ET
regulatory
Items 3.01, 7.01, 9.01
same SEC item: 7.01
same event type: regulatory
similar materiality
Filing page
SEC filing
BCDA
BioCardia Japan PMDA supports CardiAMP cell therapy submission for HFrEF; submission planned Q4 2026
BioCardia, Inc.
May 28, 2026, 8:00 AM ET
regulatory
Items 7.01, 9.01
same SEC item: 7.01
same event type: regulatory
similar materiality
Filing page
SEC filing
CHAR
Charlton Aria receives Nasdaq delinquency notice for untimely Q1 10-Q filing
Charlton Aria Acquisition Corp
May 27, 2026, 4:41 PM ET
regulatory
Items 3.01, 7.01, 9.01
same SEC item: 7.01
same event type: regulatory
similar materiality
Filing page
SEC filing
JAGX
Jaguar Health regains Nasdaq Bid Price compliance; monitoring until May 2027
Jaguar Health, Inc.
May 27, 2026, 9:10 AM ET
regulatory
Items 7.01, 8.01, 9.01
same SEC item: 7.01
same event type: regulatory
similar materiality
Filing page
SEC filing
VSTD
Vestand receives Nasdaq delisting notice for late quarterly and annual filings
Vestand Inc.
May 26, 2026, 5:18 PM ET
regulatory
Items 3.01, 7.01, 9.01
same SEC item: 7.01
same event type: regulatory
similar materiality
Filing page
SEC filing
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.